研究者業績

櫻井 浩平

サクライ コウヘイ  (Kouhei Sakurai)

基本情報

所属
藤田医科大学 医学部 臨床検査科 講師
学位
博士(医学)

研究者番号
10608756
J-GLOBAL ID
201501002143037973
researchmap会員ID
B000244891

外部リンク

学歴

 2

論文

 36
  • Kanata Kojima, Kouhei Sakurai, Tatsuya Ando, Yasuhiro Sakai, Mako Ochiai, Taku Kato, Hiroyasu Ito
    Medical Molecular Morphology in press 2025年  査読有り
    Prospero homeobox protein 1 (PROX1) is aberrantly expressed in tumors, including neuroendocrine neoplasms (NENs); however, the detailed expression pattern remains elusive. This study aimed to immunohistochemically assess PROX1 expression. Immunohistochemistry (IHC) for PROX1 was performed on tissue microarrays of normal tissues (n = 107), NENs (n = 152) (small cell lung carcinoma [SCLC], lung carcinoid [LC], gastroenteropancreatic-NEN [GEP-NEN], esophageal neuroendocrine carcinoma [ENEC], medullary thyroid carcinoma [MTC], neuroblastoma [NB], and pheochromocytoma [PHEO]), and non-NENs (n = 469). In normal tissues, PROX1 was expressed in lymphatic endothelial cells and a subset of epithelial cells in the gastrointestinal tract and the distal convoluted tubules. In NENs, the positive expression was observed in the nucleus of tumor cells in 19/26 SCLC (73.1%), 13/16 LC (81.3%), 10/15 GEP-NEN (66.7%), 2/2 ENEC (100%), 17/43 MTC (39.5%), 1/25 NB (4.0%), and 0/25 PHEO (0%). Although PROX1 was negative in many non-NENs, our analysis revealed high expression in certain cases with medulloblastoma and one case with juvenile granulosa cell tumor. PROX1 was expressed in specific cases with epithelial NENs and some cases with non-NENs. Analysis of PROX1 should provide insights into the molecular characteristics of distinct tumors.
  • Kouhei Sakurai, Tatsuya Ando, Yasuhiro Sakai, Yuichiro Mori, Satoru Nakamura, Taku Kato, Hiroyasu Ito
    Human Cell 2024年8月  査読有り筆頭著者責任著者
  • Yuya Ishihara, Hiroyuki Naruse, Hidetsugu Fujigaki, Reiko Murakami, Tatsuya Ando, Kouhei Sakurai, Komei Uehara, Koki Shimomae, Eirin Sakaguchi, Hidekazu Hattori, Masayoshi Sarai, Junnichi Ishii, Ryosuke Fujii, Hiroyasu Ito, Kuniaki Saito, Hideo Izawa
    Vaccines 12(7) 786-786 2024年7月17日  査読有り
    Preexisting cardiovascular disease (CVD) is a pivotal risk factor for severe coronavirus disease 2019 (COVID-19). We investigated the longitudinal (over 1 year and 9 months) humoral and cellular responses to primary series and booster doses of mRNA COVID-19 vaccines in patients with CVD. Twenty-six patients with CVD who received monovalent mRNA COVID-19 vaccines were enrolled in this study. Peripheral blood samples were serially drawn nine times from each patient. IgG against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike receptor-binding domain (RBD) was measured using an enzyme-linked immunosorbent assay. The numbers of interferon-γ-releasing cells in response to SARS-CoV-2 peptides were measured using an enzyme-linked immunospot assay. The RBD-IgG titers increased 2 weeks after the primary series and booster vaccination and waned 6 months after vaccination. The S1-specific T cell responses in patients aged < 75 years were favorable before and after booster doses; however, the Omicron BA.1-specific T cell responses were poor. These results suggest that regular vaccination is useful to maintain long-term antibody levels and has implications for booster dose strategies in patients with CVD. Additional booster doses, including Omicron variant-adapted mRNA vaccines, may be recommended for patients with CVD, regardless of age.
  • Kouhei Sakurai, Hiroyasu Ito
    Life sciences 343 122544-122544 2024年4月15日  筆頭著者責任著者
    Long non-coding RNAs (lncRNA) are functional RNAs, with over 200 nucleotides in length and lacking protein-coding potential. Studies have indicated that lncRNAs are important gene regulators under physiological conditions. Aberrant lncRNA expression is associated with the initiation and progression of various diseases, including cancers. High-throughput transcriptome analyses have revealed thousands of lncRNAs as putative tumor suppressors or promoters in various cancers, but the detailed molecular mechanisms of each lncRNA remain unclear. Downregulated RNA In Cancer, inhibitor of cell invasion and migration (DRAIC) (also known as LOC145837 and RP11-279F6.1) is a lncRNA that inhibits or promotes cancer progression with several modes of action. DRAIC was originally identified as a tumor-suppressive lncRNA in prostate adenocarcinoma. Subsequent studies also revealed that it has an anti-tumor role in glioblastoma, triple-negative breast cancer, and stomach adenocarcinoma. However, DRAIC exhibits oncogenic functions in other malignancies, such as lung adenocarcinoma and esophageal carcinoma, indicating its highly context-dependent effects on cancer progression and clinical outcomes. DRAIC and its associated pathways regulate various biological processes, including proliferation, invasion, metastasis, autophagy, and neuroendocrine function. This review introduces the multifaceted roles of DRAIC, particularly in cancer progression, and discusses its biological significance and clinical implications.
  • Kouhei Sakurai, Seiji Yamada, Rika Ito, Mako Ochiai, Tatsuya Ando, Yasuhiro Sakai, Taku Kato, Hiroyasu Ito
    Non-coding RNA Research 9(1) 76-83 2024年3月  査読有り筆頭著者責任著者
  • Chihiro Takeuchi, Junichi Sato, Nobutake Yamamichi, Natsuko Kageyama-Yahara, Akiko Sasaki, Takemi Akahane, Rika Aoki, Shigemi Nakajima, Masayoshi Ito, Mitsue Yamamichi, Yu-Yu Liu, Nobuyuki Sakuma, Yu Takahashi, Yoshiki Sakaguchi, Yosuke Tsuji, Kouhei Sakurai, Shuta Tomida, Keiko Niimi, Toshikazu Ushijima, Mitsuhiro Fujishiro
    Journal of Gastroenterology 2023年11月14日  査読有り
    Abstract Background Autoimmune gastritis (AIG) is a prevalent chronic inflammatory disease with oncogenic potential that causes destruction of parietal cells and severe mucosal atrophy. We aimed to explore the distinctive gene expression profiles, activated signaling pathways, and their underlying mechanisms. Methods A comprehensive gene expression analysis was conducted using biopsy specimens from AIG, Helicobacter pylori-associated gastritis (HPG), and non-inflammatory normal stomachs. Gastric cancer cell lines were cultured under acidic (pH 6.5) conditions to evaluate changes in gene expression. Results Gastric mucosa with AIG had a unique gene expression profile compared with that with HPG and normal mucosa, such as extensively low expression of ATP4A and high expression of GAST and PAPPA2, which are involved in neuroendocrine tumorigenesis. Additionally, the mucosa with AIG and HPG showed the downregulation of stomach-specific genes and upregulation of small intestine-specific genes; however, intestinal trans-differentiation was much more prominent in AIG samples, likely in a CDX-dependent manner. Furthermore, AIG induced ectopic expression of pancreatic digestion-related genes, PNLIP, CEL, CTRB1, and CTRC; and a master regulator gene of the lung, NKX2-1/TTF1 with alveolar fluid secretion-related genes, SFTPB and SFTPC. Mechanistically, acidic conditions led to the downregulation of master regulator and stemness control genes of small intestine, suggesting that increased environmental pH may cause abnormal intestinal differentiation in the stomach. Conclusions AIG induces diverse trans-differentiation in the gastric mucosa, characterized by the transactivation of genes specific to the small intestine, pancreas, and lung. Increased environmental pH owing to AIG may cause abnormal differentiation of the gastric mucosa.
  • Kouhei Sakurai, Tatsuya Ando, Yuka Ideta, Yuichiro Hayashi, Junichi Baba, Kenji Mitsudo, Hiroyasu Ito
    Anticancer Research 43(9) 3905-3911 2023年9月  査読有り筆頭著者責任著者
  • Taku Kato, Kyojiro Kawakami, Kosuke Mizutani, Tatsuya Ando, Yasuhiro Sakai, Kouhei Sakurai, Shohei Toyota, Hidetoshi Ehara, Hiroyasu Ito, Masafumi Ito
    Cancer Genomics & Proteomics 20(5) 456-468 2023年9月  査読有り
  • Kouhei Sakurai, Akira Nagai, Tatsuya Ando, Yasuhiro Sakai, Yuka Ideta, Yuichiro Hayashi, Junichi Baba, Kenji Mitsudo, Masaharu Akita, Nobutake Yamamichi, Hidetsugu Fujigaki, Taku Kato, Hiroyasu Ito
    Cancer Genomics & Proteomics 20(1) 64-74 2023年  査読有り筆頭著者責任著者
  • Daisuke Ohki, Nobutake Yamamichi, Yoshiki Sakaguchi, Yu Takahashi, Natsuko Kageyama-Yahara, Mitsue Yamamichi, Chihiro Takeuchi, Yosuke Tsuji, Yasuhiro Sakai, Kouhei Sakurai, Shuta Tomida, Kazuhiko Koike, Mitsuhiro Fujishiro
    Cancer medicine 11(24) 5066-5078 2022年5月10日  査読有り
    The objective of this study was to elucidate the molecular background of sessile serrated adenoma/polyp (SSA/P) endoscopically resected with comprehensive gene expression analysis. Gene expression profiling was performed for 10 tumor-normal pairs of SSA/P. Cluster analysis, gene set enrichment analysis (GSEA), and consensus molecular subtype (CMS) classification of colorectal cancer (CRC) were applied to our transcriptome analysis. Unsupervised cluster analysis showed that the gene expression profile of SSA/Ps is different from that of adjacent normal epithelial cells, even in the very early stage of tumorigenesis. According to the CMS classification, our microarray data indicated that SSA/Ps were classified as CMS1. GSEA demonstrated a strong association between SSA/P and microsatellite instability-high (MSI-H) CRC (p < 10-5 ). Transcriptome analysis of five MSI-related genes (MSH2, MSH6, MLH1, PMS1, and PMS2) and five CRC-related genes (BRAF, KRAS, APC, TP53, and CDX2) showed that CDX2 expression was most severely decreased in SSA/P. Immunohistochemical staining confirmed that CDX2 protein was reduced compared with the surrounding mucosa. Direct sequencing of the BRAF gene showed that the BRAF V600E mutation was detected in only nine of 36 cases. In a mouse model, BRAF, APC, or CDX2 deficiency indicated that the gene expression pattern with loss of CDX2 is more similar to our SSA/Ps compared with those induced by BRAF or APC mutation. Transcriptome analysis of SSA/Ps showed characteristic gene expression with a strong resemblance to MSI-H CRC. Downregulation of CDX2 expression is an essential molecular mechanism involved in the initial stage of SSA/P tumorigenesis. (UMIN000027365).
  • Yuka Ideta, Takanobu Tagawa, Yuichiro Hayashi, Junichi Baba, Kimiko Takahashi, Kenji Mitsudo, Kouhei Sakurai
    Cancer Genomics & Proteomics 18(1) 17-27 2021年1月  査読有り最終著者責任著者
  • 島寛太, 櫻井浩平, 酒井康弘, 山田勢至, 中川満, 神永有紗, 一安泰佑, 塚本徹哉, 松山篤二, 浦野誠
    診断病理 37(4) 2020年  査読有り
  • Kouhei Sakurai, Takanori Onouchi, Seiji Yamada, Youichirou Baba, Tetsuya Murata, Tetsuya Tsukamoto, Makoto Kuroda, Makoto Urano
    Malaysian Journal of Pathology 41(3) 339-343 2019年12月  査読有り筆頭著者
  • Makoto Urano, Masato Nakaguro, Yoshinari Yamamoto, Hideaki Hirai, Maki Tanigawa, Natsuki Saigusa, Akira Shimizu, Kiyoaki Tsukahara, Yuichiro Tada, Kouhei Sakurai, Madoka Isomura, Yuki Okumura, Hiroshi Yamaguchi, Jun Matsubayashi, Toshitaka Nagao
    The American Journal of Surgical Pathology 43(7) 984-994 2019年7月  査読有り
    Epithelial-myoepithelial carcinoma (EMC) is a rare salivary gland tumor that is histologically characterized by biphasic tubular structures composed of inner ductal and outer clear myoepithelial cells. Because of its histologic variety, it is sometimes challenging to make an accurate diagnosis, and useful ancillary tests are essential for this purpose. We investigated 87 cases of EMC arising in the major and minor salivary glands and seromucinous glands in the nasal cavity or bronchus to describe the histologic features and mutation status of selected key oncogenes. Classic EMC accounted for 40.2% of all cases. Other cases showed various growth patterns and cytologic features in addition to the typical histology; cribriform patterns, a basaloid appearance, and sebaceous differentiation were relatively common (17.2% to 18.4%), whereas oncocytic/apocrine, papillary-cystic, double-clear, squamous, psammomatous, Verocay-like, and high-grade transformation were rare. HRAS mutations were found in 82.7% of EMCs and were concentrated in codon 61. There was no significant correlation between the HRAS mutation status and the histology. No EMC ex pleomorphic adenoma cases had HRAS mutations. PIK3CA and/or AKT1 mutations were the second most frequent mutations (20.7%, 6.5%, respectively) and almost always cooccurred with HRAS mutations. It is noteworthy that the HRAS mutation was not identified in any salivary gland tumor entities manifesting EMC-like features, including adenoid cystic carcinoma, pleomorphic adenoma, basal cell adenoma/adenocarcinoma, and myoepithelial carcinoma. We conclude that HRAS mutations are a frequent tumorigenic gene alteration in EMC, despite its histologic diversity. This study provides further insight into strategies for diagnosing EMC and discriminating it from its mimics.
  • Seiji Yamada, Sumihito Nobusawa, Tatsuya Yamazaki, Takao Teranishi, Sadayoshi Watanabe, Kazuhiro Murayama, Shigeo Ohba, Asako Okabe, Kouhei Sakurai, Makoto Urano, Tetsuya Tsukamoto, Hideaki Yokoo, Yuichi Hirose, Masato Abe
    Pathology International 69(6) 372-377 2019年6月19日  
    Glioneuronal tumor (GNT) is a rare central nervous system neoplasm composed of glial and neuronal components. Making the specific diagnosis of GNT can be challenging due to histopathological and genetical similarities among some GNTs and low‐grade gliomas. We report a case of GNT with rosette‐forming glioneuronal tumor, dysembryoplastic neuroepithelial tumor, and pilocytic astrocytoma‐like morphology harboring FGFR1 mutation. A 16‐year‐old female presented with absence seizures. Magnetic resonance imaging revealed a right temporal lobe mass with multinodular enhancement by gadolinium administration. The tumor was mostly composed of oligodendrocyte‐like cells (OLCs) with variable perinuclear haloes. Abundant Rosenthal fibers and eosinophilic granular bodies were identified. Neither mitotic figures nor areas of necrosis were seen. Focal neurocytic rosette features, involving ring‐like arrays of OLCs around eosinophilic cores, were observed. Direct sequencing showed a missense mutation in FGFR1 K656E, whereas FGFR1 N546K, PIK3CA, and BRAF V600E were intact. KIAA1549‐BRAF fusion was not detected by fluorescence in situ hybridization analysis.
  • Uga N, Suzuki T, Sakurai K, Tsukamoto T, Tuchiya T, Kondo Y, Naoe A, Watanabe S, Yasui T, Hara F
    Journal of Pediatric Surgery Case Reports 45 2019年4月  査読有り
  • Okabe, A., Kiriyama, Y., Suzuki, S., Sakurai, K., Teramoto, A., Kato, H., Naiki-Ito, A., Tahara, S., Takahashi, S., Kuroda, M., Sugioka, A., Tsukamoto, T.
    Journal of Toxicologic Pathology 32(2) 2019年  査読有り
  • Nakayama C, Yamamichi N, Tomida S, Takahashi Y, Kageyama-Yahara N, Sakurai K, Takeuchi C, Inada KI, Shiogama K, Nagae G, Ono S, Tsuji Y, Niimi K, Fujishiro M, Aburatani H, Tsutsumi Y, Koike K
    Cancer Science 109(12) 3853-3864 2018年10月  査読有り
  • Chihiro Minatsuki, Nobutake Yamamichi, Ken-Ichi Inada, Yu Takahashi, Kouhei Sakurai, Takeshi Shimamoto, Yosuke Tsuji, Kazuya Shiogama, Shinya Kodashima, Yoshiki Sakaguchi, Keiko Niimi, Satoshi Ono, Toru Niwa, Ken Ohata, Nobuyuki Matsuhashi, Masao Ichinose, Mitsuhiro Fujishiro, Yutaka Tsutsumi, Kazuhiko Koike
    Digestive Diseases and Sciences 63(10) 2617-2625 2018年10月  査読有り
  • Takahashi Y, Yamamichi N, Inada KI, Shiogama K, Sakurai K, Takeuchi C, Mizutani Y, Tsutsumi Y, Koike K
    Pathology International 68(10) 557-562 2018年9月  査読有り
  • Sakurai K, Tsukamoto T
    Non-coding RNA Investigation 2018年3月  査読有り招待有り筆頭著者
  • Wasano K, Sakurai K, Kawasaki T, Kusafuka K, Kasahara M, Kondo N, Inada KI, Ogawa K
    Rare Tumors 10 2036361318798867 2018年  査読有り責任著者
  • Mahmood A. Hamed, Seiichi Nakata, Kazuya Shiogama, Kenji Suzuki, Ramadah H. Sayed, Yoichi Nishimura, Noboru Iwata, Kouhei Sakurai, Badawy S. Bedawy, Ken-ichi Inada, Hayato Tsuge, Yutaka Tsutsumi
    Clinical and Experimental Otorhinolaryngology 10(3) 213-220 2017年9月  査読有り
  • Kazuya Shiogama, Takanori Onouchi, Yasuyoshi Mizutani, Kouhei Sakurai, Ken-ichi Inada, Yutaka Tsutsumi
    Acta Histochemica et Cytochemica 49(4) 109-116 2016年  査読有り
  • Takanori Onouchi, Kazuya Shiogama, Takahiro Matsui, Yasuyoshi Mizutani, Kouhei Sakurai, Ken-ichi Inada, Yutaka Tsutsumi
    Acta Histochemica et Cytochemica 49(4) 117-123 2016年  査読有り
  • Yasuyoshi Mizutani, Kazuya Shiogama, Takanori Onouchi, Kouhei Sakurai, Ken-ichi Inada, Yutaka Tsutsumi
    Acta Histochemica et Cytochemica 49(1) 7-19 2016年  査読有り
  • Kouhei Sakurai, Brian J. Reon, Jordan Anaya, Anindya Dutta
    13(5) 828-838 2015年5月  査読有り筆頭著者
  • Kazuyoshi Kobayashi, Kouhei Sakurai, Hiroaki Hiramatsu, Ken-ichi Inada, Kazuya Shiogama, Shinya Nakamura, Fumiko Suemasa, Kyosuke Kobayashi, Seiya Imoto, Takeshi Haraguchi, Hiroaki Ito, Aya Ishizaka, Yutaka Tsutsumi, Hideo Iba
    Scientific Reports 5 8428 2015年2月  査読有り
  • Takanobu Tagawa, Takeshi Haraguchi, Hiroaki Hiramatsu, Kazuyoshi Kobayashi, Kouhei Sakurai, Ken-Ichi Inada, Hideo Iba
    Biochemical Journal 447(3) 449-455 2012年11月  査読有り
  • Ishizaka A, Mizutani T, Kobayashi K, Tando T, Sakurai K, Fujiwara T, Iba H
    Journal of Biological Chemistry 287(15) 11924-11933 2012年4月  査読有り
  • Kouhei Sakurai, Chihiro Furukawa, Takeshi Haraguchi, Ken-ichi Inada, Kazuya Shiogama, Takanobu Tagawa, Shuji Fujita, Yoshihito Ueno, Aya Ogata, Mai Ito, Yutaka Tsutsumi, Hideo Iba
    Cancer Research 71(5) 1680-1689 2011年3月  査読有り筆頭著者
  • Aya Ogata, Chihiro Furukawa, Kouhei Sakurai, Hideo Iba, Yukio Kitade, Yoshihito Ueno
    Bioorganic & Medicinal Chemistry Letters 20(24) 7299-7302 2010年12月  査読有り筆頭著者
  • Nobutake Yamamichi, Ken-ichi Inada, Chihiro Furukawa, Kouhei Sakurai, Toshio Tando, Aya Ishizaka, Takeshi Haraguchi, Taketoshi Mizutani, Mitsuhiro Fujishiro, Ryoichi Shimomura, Masashi Oka, Masao Ichinose, Yutaka Tsutsumi, Masao Omata, Hideo Iba
    Experimental Cell Research 315(10) 1779-1789 2009年6月  査読有り
  • Nobutake Yamamichi, Ryoichi Shimomura, Ken-ichi Inada, Kouhei Sakurai, Takeshi Haraguchi, Yuka Ozaki, Shuji Fujita, Taketoshi Mizutani, Chihiro Furukawa, Mitsuhiro Fujishiro, Masao Ichinose, Kazuya Shiogama, Yutaka Tsutsumi, Masao Omata, Hideo Iba
    Clinical Cancer Research 15(12) 4009-4016 2009年6月  査読有り
  • Shuji Fujita, Taiji Ito, Taketoshi Mizutani, Shigeru Minoguchi, Nlobutake Yamamichi, Kouhei Sakurai, Hlideo Iba
    Journal of Molecular Biology 378(3) 492-504 2008年5月  査読有り
  • Taiji Ito, Hirotaka Watanabe, Nobutake Yamamichi, Shunsuke Kondo, Toshio Tando, Takeshi Haraguchi, Taketoshi Mizutani, Kouhei Sakurai, Shuji Fujita, Tomonori Izumi, Toshiaki Isobe, Hideo Iba
    Biochemical Journal 411(1) 201-209 2008年4月  査読有り

MISC

 24

講演・口頭発表等

 4

担当経験のある科目(授業)

 6

共同研究・競争的資金等の研究課題

 11

その他

 1
  • 日本分子生物学会、日本病理学会、日本臨床細胞学会、日本食品安全協会、日本動物実験代替法学会